Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in High Risk Childhood Relapsed ALL
NCT03590171Phase 2Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Modified Peptides
- Countries
- 15
01
Overview
A Phase 2 trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Charité – Universitätsmedizin Berlin. Started Sep 2017; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03590171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590171.